Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TBMF conditioning regimen for R/R or MRD-positive AML post allo-HSCT
ChiCTR2600130758Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of thiotepa and melphalan in acute myeloid leukemia (AML), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Relapse-free survival at 1 year. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
thiotepamelphalan
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2600130758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130758.